We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
32.50 | 1.85% | 1,788.50 | 1,788.50 | 1,789.00 | 1,792.50 | 1,740.50 | 1,743.50 | 10,458,053 | 16:35:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.95 | 73.65B |
Date | Subject | Author | Discuss |
---|---|---|---|
21/2/2020 11:40 | milehouse, look at the forward earnings guidance given re GSK v AZN. There is little comparison atm, AZN is enjoying a purple patch. Astra Net debt is also approx 50% lower than GSK. | essentialinvestor | |
21/2/2020 11:29 | M, Adjusted profit fell short of forecasts, seems the shine has come off GSK and market is selling it down. Market expecting great things of EW, but now she has also stated the proposed alliance will cost GSK £2.4b. | beckers2008 | |
21/2/2020 11:03 | Similar to the performance of RDSB v BP. spud | spud | |
21/2/2020 11:00 | Can anyone explain why this stock has performed so poorly since results? If we compare it to AZ, results were better and the hit has been far greater. The exposure that AZ has to China and the coronavirus too is monumental, they are the largest pharma there. GSK is down >10% since the results and AZ is higher...?! | milehouse | |
21/2/2020 10:40 | Well, I was holding at average £14.50 last summer, so anything goes in my experience. | daveboy1 | |
21/2/2020 09:18 | When is this decline gonna stop! Sold out on the day of poor results and may buy back in again at £16? Or am i being too optimistic? | beckers2008 | |
21/2/2020 08:18 | GBP 1.0 = USD 1.29 | tradermichael | |
20/2/2020 15:30 | This is a slightly more technical press release: US-German immunooncology specialist Immatics Biotechnologies GmbH has licensed two of its TCR-T programs to GlaxoSmithKline for US$50m upfront. The companies’ strategic alliance aims to equip patients' own T cells with a natural T cell receptor that recognises antigens on solid tumours. Under the agreement, GlaxoSmithKline plc (GSK) acquires the commercialisation rights for two TCR-T programs from the former cancer vaccine developer paying US$50m. GSK intends to invest heavily in immatics' know-how in the identification of patient-specific tumour neoantigens using its proprietary XPresident platform and the further development of the programmes. The British company plans to spend more than US$550m in milestones for each of the programmes designed to treat various solid tumour iindications. In addition, Immatics is eglible to receive royalties on sales upon market approval. Under the terms of the agreement, the partners will initially develop autologous T-cell therapies. However, GSK also has the option to licence Immatics' ACTallo® technology, which delivers allogenic TCR-Ts. Allogenic cell production is expected to largely to reduce costs and length of hospital stay because - in contrast to allogenic cell therapies – they can be manufactured centralised and thus promise to reduce production costs compared to autologous T-cell therapies. The licensed TCRs were identified using Immatics' XCEPTOR® TCR platform and are directed against two proprietary cancer targets on the cancer cell surface. GSK has also acquired an option to add additional cancer targets identified by Immatics' XPresident platform. For these targets, GSK will receive additional option and milestone payments as well as royalties. While the team led by Immatics CEO Harpreet Singh is primarily responsible for the preclinical development and validation of the TCR-T candidates, GSK will be responsible for their clinical development, approval and worldwide marketing. Immatics also has the possibility to co-develop one or more candidates and conduct first-in-man trials, if GSK agrees. | tradermichael | |
20/2/2020 12:02 | DNL about to explode , Institutional investor added 1 million shares this week . LOTS of BIG NEWS around the corner =10+ BAGGER GEM RALLLYYYYYYYYYYYY Diurnal (DNL) Market Cap £27 M Price: 31p Upcoming Catalysts: MAA-Acceptance for Chronocort in February/March 2020 Alkindi approval in Israel expected in 2Q 2020 Alkindi approval in Australien expected in 2Q 2020 US-Partnership for Alkindi & Chronocort expected in 1H 2020 Alkindi & Chronocort Partnership for Asia für Japan und China US-Approval for Alkindi expected in 4Q 2020 EU Approval for Chronocort expected in 4Q/1Q 2020/21 Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses | bioking | |
20/2/2020 11:41 | Agree, but here's two more: Clinical-stage biotechnology business Immatics said Thursday that GlaxoSmithKline will license two of its T-cell therapy candidates being developed to treat cancer for a $50 million upfront payment. Under the terms of the agreement, Glaxo will be responsible for developing, manufacturing and commercializing the investigative treatments. Immatics said that, in addition to the award upfront, is eligible for over $550 million in development, regulatory and commercial payments for each product, plus royalties. The collaboration deal also includes the option for the British pharmaceutical company to license additional candidates. German biotech startup Immatics said that it is developing treatments that uses natural or engineered T-cells, a kind of immune cell, to fight solid tumors. This latest deal brings Glaxo's cell-therapy pipeline up to six assets, from four previously. In Europe there are currently two approved cell-therapy products, both to treat certain blood cancers, developed by drug makers Gilead Science and Novartis. | tradermichael | |
20/2/2020 11:15 | 2250 you reckon MJ, yes possible. Need some progress on the pipeline to see that though?. | essentialinvestor | |
20/2/2020 11:10 | That would be very nice. I think the company would like to strengthen free cash flow and build free cash flow cover of the annual dividend to a target range of 1.25-1.50x, before returning the dividend to growth. | tradermichael | |
20/2/2020 10:48 | TM, excluding the special dividend it has been 80p since 2015. Time for a slight increase I would have thought :-) | sicker | |
20/2/2020 10:00 | I don't look at it as 'dropped', because I have not sold and don't intend to sell at a loss! (Also, I did not buy my shares at the 'top'). This company is going through a massive re-profiling and the new products plus Consumer Health split will bring the equivalent value of 2250p per share. That's a good return with 80p per year dividend for however long it takes …. ;0) | tradermichael | |
20/2/2020 09:54 | ....So you have dropped 90k in just one month. Going to take 10 dividend payments to recover that. | montedawnster | |
20/2/2020 09:39 | 23p per share ex dividend today. My £9.8K dividend will buy some more GSK shares come payment on 9th April ….. ;o) On to Q1 next (19p per share ;0)) | tradermichael | |
19/2/2020 13:59 | Agree with Woodhawk... CtR isn't adding information which specifically relates to GSK. May be vaguely interesting in a general discussion of disease control but in reality it's very peripheral to enhancing fact-based knowledge. So, like Woodhawk, filter button is the only option now for Crossing the Rubicon. | grahamburn | |
19/2/2020 11:49 | Nothing wrong with chats on a women's night out, Montedawnster. Beats talking about sport and cars any day. ;) Agree with your first sentence though. I've had CTR on filter for months now. | keyno | |
19/2/2020 11:10 | "The next two weeks are critical - CoronaVirus pandemic" Breakdown: 30% deaths in 60's, 30% in 70's, 20% in 80's 20% under 60. Men & women equally represented amongst confirmed cases, deaths 64% men. Kids spared. NYTimes Covid-19 20x deadlier than FLU. (22mins 50 secs in) R0 was over 3, maybe as high as 6.7 | crossing_the_rubicon | |
19/2/2020 11:07 | Reasons to be cheerful: 1. Ex dividend day tomorrow …. 23p per share | tradermichael | |
19/2/2020 10:40 | Crossing_the_Rubicon - idiot. Filtered. | woodhawk |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions